The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 Summer Meeting | A real-world analysis on pembro monotherapy versus pembro + chemotherapy for never-smoking NSCLC
Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHSFT/BTOG Steering Committee, UK, talks on a real-world investigation into whether patients with non-small cell lung cancer (NSCLC) more than 50% PD-L1 positive should have pembrolizumab monotherapy or pembrolizumab plus chemotherapy, specifically in never-smokers. The multivariate analysis data of the Phase III trials KEYNOTE-024 (NCT02142738) trial and KEYNOTE-042 (NCT02220894) had suggested poorer survival outcomes for patients with NSCLC who are never-smokers receiving pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy, which was further demonstrated by a real-world analysis. This interview took place at the BTOG 2022 Summer Meeting congress in London.
